Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Patient enrollment begun for phase 2a safety trial of salbutamol in adult asthma patients
May 18th, 2006
Lab International Inc. (LAB), an integrated drug development company with subsidiaries developing therapies for the inhalation market and providing contract research services, announced it has enrolled the first patient in its LAB CGRP phase 2a trial. The trial is expected to be completed in the third quarter of 2006. The objectives of this randomized, double blind, cross-over phase 2 study are to investigate the protective efficacy of LAB CGRP on metacholine induced bronchial hyper-responsiveness in adult patients with mild to moderate asthma, to compare this efficacy to salbutamol and placebo and to evaluate the safety and tolerability of LAB CGRP...
Source: Biotech Business Week (2006-05-18)
|
